
Clinical Science (2010) 118, (459461) (Printed in Great Britain)
Commentary
Clopidogrel application: beyond coronary artery disease
Chunyu Zeng*†
*Department of Cardiology, Daping Hospital, The Third Military Medical University, Chongqing, People's Republic of China, and †Department of Cardiology, The First Affiliated Hospital, Shantou Medical College, Shantou University, Shantou City, People's Republic of China
Key words: ADP, angiotensin II, clopidogrel, endothelium, hypertension, mesenteric artery, P2Y receptor.
Abbreviations: ACC, American College of Cardiology; AHA, American Heart Association; AngII, angiotensin II; CABG, coronary artery bypass grafting; CHARISMA, Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance; CURE, Clopidogrel in Unstable angina to prevent Recurrent Events; FDA, Federal Drug Administration; 2-MeS-ADP, 2-methylthio-ADP; PAD, peripheral artery disease.
Correspondence: Dr Chunyu Zeng (cyzeng1@hotmail.com).
Dual antiplatelet therapy with aspirin and clopidogrel, a P2Y12 antagonist, is a cornerstone for treatment of patients with stroke, peripheral arterial disease and acute coronary artery disease, followed with or without percutaneous coronary intervention. In the present issue of Clinical Science, Giachini and co-workers found that clopidogrel could normalize the increased phenylephrine-induced vascular contraction and the impaired acetylcholine-induced vasodilation in mesenteric arteries from AngII (angiotensin II)-infused Sprague–Dawley rats. This might develop a new area for clopidogrel application; however, whether clopidogrel can improve arterial function in patients with hypertension or diabetes, or if clopidogrel outweighs the beneficial effect of aspirin in those patients, remains an open field for future inquiry.
Received 28 October 2009/2 November 2009; accepted 4 November 2009
Published as Immediate Publication 4 November 2009, doi:10.1042/CS20090546
© The Authors Journal compilation © 2010 Biochemical Society
|